LillyDirect offers self-pay prices and easy access, but a Senate report raises questions about steering + cost. See how it works and what to watch.
An honest Framework review from a 2-year compounded tirzepatide patient: flat pricing, sub-3-day shipping, and how to verify the pharmacy sourcing.
How to order at restaurants on Ozempic, Wegovy, or Zepbound. What to eat, what triggers nausea, portion tactics, alcohol, and the social side.
Why is it so hard to eat less? Hunger hormones, brain reward, and why a theory explain what's actually happening, and why willpower is not the issue.
Medicaid coverage for GLP-1s expands through December 2031 under the BALANCE Model. Eligibility, pricing, and what to ask your state Medicaid agency.
California AB 1990 cleared Appropriations 13-0 and heads to the Assembly floor. Latest amendments, opposition, and what it means for GLP-1 patients.
Lilly wants retatrutide classified as a biologic, but the FDA is not agreeing, now there is a lawsuit. What the lawsuit and OFA brief actually say.
Lost weight on a GLP-1 and worried a new provider won’t approve? Here is what the FDA labels, the research, and Medicare’s $50 program actually say.
GLP-1 patients say their medication can feels weaker. Research points to body adaptation, sleep, stress, and hormonal shifts as the usual culprits.
Worried about “Ozempic personality”? The FDA’s 2026 review of 107,910 patients tells a more reassuring story than the headlines do.
A new mouse study suggests pausing a GLP-1 makes restarts less effective. Here is how strong the evidence is and what to think about before a break.
Canada is approving generic Ozempic, India already has. Here is what it means for US prices, when patents expire, and what you can actually do today.
